| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6699871 | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(1 year, 9 months ago) | |
| US7326708 | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Apr, 2026
(1 year, 11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6303661 | MERCK SHARP DOHME | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
Apr, 2017
(7 years ago) | |
| US6890898 | MERCK SHARP DOHME | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
| US7078381 | MERCK SHARP DOHME | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
| US7459428 | MERCK SHARP DOHME | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
| US8168637 | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment of diabetes |
Jun, 2022
(1 year, 10 months ago) | |
| US7125873 | MERCK SHARP DOHME | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(1 year, 9 months ago) | |
|
US7125873 (Pediatric) | MERCK SHARP DOHME | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(1 year, 2 months ago) | |
|
US6699871 (Pediatric) | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(1 year, 2 months ago) | |
|
US7326708 (Pediatric) | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Oct, 2026
(2 years from now) | |
Juvisync is owned by Merck Sharp Dohme.
Juvisync contains Simvastatin; Sitagliptin Phosphate.
Juvisync has a total of 11 drug patents out of which 9 drug patents have expired.
Expired drug patents of Juvisync are:
- US6303661
- US6890898
- US7078381
- US7459428
- US8168637
- US7125873
- US7125873*PED
- US6699871*PED
- US6699871
Juvisync was authorised for market use on 18 September, 2012.
Juvisync is available in tablet;oral dosage forms.
Juvisync can be used as method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and simvastatin is appropriate, method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and simvastatin is appropriate, in combination with metformin, method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and simvastatin is appropriate, in combination with insulin.
The generics of Juvisync are possible to be released after 11 October, 2026.
Drugs and Companies using SIMVASTATIN; SITAGLIPTIN PHOSPHATE ingredient
Market Authorisation Date: 18 September, 2012
Treatment: Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and simvastatin is appropriate; Method of treating type 2 diabetes mellitus in patients for whom treatm...
Dosage: TABLET;ORAL
JUVISYNC family patents
